Peel Hunt is acting as NOMAD and Corporate Broker to Sinclair IS Pharma plc on its proposed disposal of its non-aesthetics business to Alliance Pharma for a total upfront cash consideration of £132 m plus sales related royalty payments relating to Flammacerium US, as announced on 26 November, 2015.
